OM DENNE EPISODE
Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investors, and how the business of journalism does and doesn't affect the types of stories he writes.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af Off-Target Effects with Matt Gline.
ANDRE EPISODE I DENNE PODCAST
For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and knowledge of investing in China biotech over the years. They discuss the rise of China biotech and how it might or might not be impacting M&A in the sector.
One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biotech has a structural problem regarding how companies 'innovate' today and the different market strategies of investors.
Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, dru…
Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jeff…
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra BiotechTV, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
